Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1741-1743

  Improta, Giuseppina ^a   Zupa, Angela ^a   Possidente, Luciana ^a   Tartarone, Alfredo ^b   Pedicini, Piernicola ^b   Nappi, Antonio ^b   Molinari, Sergio ^b   Fraggetta, Filippo ^c   Vita, Giulia ^b  

^a Laboratory of Clinical Research and Molecular Diagnostics   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c CANNIZZARO HOSPITAL   (Italy)

Author keywords

Colorectal cancer; KRAS; Multiple mutations; Tumoral heterogeneity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADENOCARCINOMA; ADJUVANT THERAPY; AGED; ARTICLE; CASE REPORT; CELL HETEROGENEITY; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE AMPLIFICATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE DISSECTION; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; RECTUM BIOPSY; RECTUM HEMORRHAGE; RECTUM RESECTION; SEQUENCE ANALYSIS; SOMATIC MUTATION; SPECTROPHOTOMETER; TENESMUS; TUMOR REGRESSION;

EID: 84875747882     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1255     Document Type: Article

References (26)

1. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892, 2012.
2. Baldus SE, Schaefer KL, Engers R, Hartleb D, et al: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799, 2010.
3. Marusyk A and Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805: 105-117, 2010.
4. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008.
5. Jönsson M, Ekstrand A, Edekling T, et al: Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. BMC Clin Pathol 9: 8, 2009.
6. Moerkerk P, Arends JW, van Driel M, et al: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376-3378, 1994.
7. Sameer AS, ul Rehman S, Pandith AA, et al: Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol 15: 244-252, 2009.
8. Sanger F, Nicklen S and Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467, 1977.
9. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
10. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. NEngl J Med 359: 1757-1765, 2008.
12. Al-Mulla F, Going JJ, Sowden ET, et al: Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 185: 130-138, 1998.
13. Albanese I, Scibetta AG, Migliavacca M, et al: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325: 784-791, 2004.
14. Mancuso A, Sollami R, Recine F, et al: Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy. J Clin Oncol 28: e756-e758, 2010.
15. Lamy A, Blanchard F, Le Pessot F, et al: Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 24: 1090-1100, 2011.
16. Bouchahda M, Karaboué A, Saffroy R, et al: Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66: 605-609, 2010.
17. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998.
18. Macedo MP, Andrade Lde B, Coudry R, et al: Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. Int J Colorectal Dis 26: 1241-1248, 2011.
19. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
20. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
21. Fialkow PJ: Clonal origin of human tumors. Annu Rev Med 30: 135-143, 1979.
22. Winder T, Mündlein A, Rhomberg S, et al: Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 21: 1283-1287, 2009.
23. Richman SD, Chambers P, Seymour MT, et al: Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 34: 61-66, 2011.
24. Spitzner M, Emons G, Kramer F, et al: A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 78: 1184-1192, 2010.
25. Pedicini P, Nappi A, Strigari L, et al: Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol 7: 143, 2012.
26. Pedicini P, Caivano R, Jereczek-Fossa BA, et al: Modelling the correlation between EGFr expression and tumor cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors. Theor Biol Med Model 9: 23, 2012.